ReviewInvestigational new drugs2002
Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.
Review in Investigational new drugs, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 90 citations in OpenAlex.
- Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.BJU international · 2013Trial
- Cancer and Covid-19: Collectively catastrophic.Cytokine & growth factor reviews · 2022Review
- Inflammasome inhibitors: promising therapeutic approaches against cancer.Journal of hematology & oncology · 2019Review
- SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway.International journal of oncology · 2017Article
- Antiangiogenic therapy effects on age-associated matrix metalloproteinase-9 (MMP-9) and insulin-like growth factor receptor-1 (IGFR-1) responses: a comparative study of prostate disorders in aged and TRAMP mice.Histochemistry and cell biology · 2014Article
- Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival.Cancer causes & control : CCC · 2010Article
- Castration-resistant prostate cancer: new science and therapeutic prospects.Therapeutic advances in medical oncology · 2010Article
- Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.The Prostate · 2010Article
- Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole.Brain research bulletin · 2010Article
- Angiogenesis inhibition in the treatment of prostate cancer.Anti-cancer agents in medicinal chemistry · 2009Review
- Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.British journal of cancer · 2009Article
- VEGF inhibitors and prostate cancer therapy.Current molecular pharmacology · 2009Review
- Anti-angiogenesis approach to genitourinary cancer treatment.Update on cancer therapeutics · 2009Article
- Monoclonal antibody therapy of chronic lymphocytic leukemia.Cancer immunology, immunotherapy : CII · 2006Review
- Effects of hormone deprivation and 2-methoxyestradiol combination therapy on hormone-dependent prostate cancer in vivo.Neoplasia (New York, N.Y.) · 2005Article
- Mechanism targeted discovery of antitumor marine natural products.Current medicinal chemistry · 2004Review
- The future in advanced prostate cancer: take your partners or is the last dance for me?Reviews in urology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most frequently diagnosed malignancy and the second most common cause of cancer-related death in men in the United States. Unfortunately, at the current time, no curative treatments are available for metastatic prostate cancer. As is the case for most solid tumors, the recruitment of blood vessels (angiogenesis) is key for the progression and metastasis of prostate cancer. Inhibition of this process is an attractive approach to treatment. Many antiangiogenic agents are currently in clinical development. The following discussion will outline the importance of angiogenesis in the metastasis and progression of prostate cancer, summarize the current surrogate markers of angiogenesis available for the drug development of antiangiogenic agents, and review examples of investigational agents that target tumor angiogenesis (e.g., TNP-470, Thalidomide, CC5013, Carboxyamido-triazole (CAI), Endostatin. SU5416, SU6668, Bevacizumab (Anti-VEGFrhuMAb), and 2-Methoxyestradiol).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.